Zentalis Pharmaceuticals Inc
ZNTL1.400USD
-0.020-1.41%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
101.14MMarket Cap
LossP/E TTM
More Details of Zentalis Pharmaceuticals Inc Company
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Zentalis Pharmaceuticals Inc Info
Ticker SymbolZNTL
Company nameZentalis Pharmaceuticals Inc
IPO dateApr 03, 2020
CEOEastland (Julie)
Number of employees166
Security typeOrdinary Share
Fiscal year-endApr 03
Address10275 Science Center Drive
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18582634333
Websitehttps://www.zentalis.com/
Ticker SymbolZNTL
IPO dateApr 03, 2020
CEOEastland (Julie)
Company Executives of Zentalis Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
Mr. Scott Myers
Mr. Scott Myers
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Julie Eastland
Ms. Julie Eastland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. James B. Bucher, J.D.
Mr. James B. Bucher, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. David Michael Johnson
Mr. David Michael Johnson
Independent Director
Independent Director
250.42K
+29.87%
Dr. Jan Skvarka, Ph.D.
Dr. Jan Skvarka, Ph.D.
Independent Director
Independent Director
194.95K
+41.94%
Dr. Enoch Kariuki, Pharm.D.
Dr. Enoch Kariuki, Pharm.D.
Independent Director
Independent Director
137.37K
+72.22%
Dr. Ingmar Bruns, M.D.
Dr. Ingmar Bruns, M.D.
Chief Medical Officer
Chief Medical Officer
36.63K
--
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Mr. Karan S. Takhar
Mr. Karan S. Takhar
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Walters (William T)
9.76%
Matrix Capital Management Company, LP
8.94%
The Vanguard Group, Inc.
4.02%
Acadian Asset Management LLC
3.94%
Two Sigma Investments, LP
3.91%
Other
69.43%
Shareholders
Shareholders
Proportion
Walters (William T)
9.76%
Matrix Capital Management Company, LP
8.94%
The Vanguard Group, Inc.
4.02%
Acadian Asset Management LLC
3.94%
Two Sigma Investments, LP
3.91%
Other
69.43%
Shareholder Types
Shareholders
Proportion
Hedge Fund
21.87%
Investment Advisor/Hedge Fund
18.23%
Individual Investor
12.68%
Investment Advisor
11.66%
Research Firm
6.60%
Venture Capital
3.27%
Corporation
1.32%
Endowment Fund
0.24%
Sovereign Wealth Fund
0.10%
Other
24.02%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
354
51.80M
71.81%
-28.72M
2025Q2
374
67.79M
93.98%
-24.60M
2025Q1
386
70.02M
97.36%
-19.46M
2024Q4
379
71.39M
100.17%
-15.78M
2024Q3
373
74.19M
104.47%
-21.21M
2024Q2
365
79.92M
112.67%
-23.64M
2024Q1
360
88.75M
125.22%
-9.75M
2023Q4
361
83.47M
118.17%
-13.77M
2023Q3
361
82.76M
117.68%
-11.58M
2023Q2
361
84.96M
121.10%
+6.07M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Walters (William T)
7.05M
9.77%
+3.05M
+76.25%
Jan 29, 2025
Matrix Capital Management Company, LP
13.96M
19.35%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.88M
4%
-375.98K
-11.53%
Jun 30, 2025
Acadian Asset Management LLC
2.80M
3.88%
+124.98K
+4.67%
Jun 30, 2025
Two Sigma Investments, LP
2.37M
3.28%
+977.03K
+70.19%
Jun 30, 2025
Renaissance Technologies LLC
1.53M
2.12%
+703.51K
+85.17%
Jun 30, 2025
Tang Capital Management, LLC
1.55M
2.15%
+50.00K
+3.33%
Jun 30, 2025
D. E. Shaw & Co., L.P.
1.20M
1.66%
+79.85K
+7.14%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Federated Hermes MDT Small Cap Core ETF
0.07%
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0%
Fidelity Fundamental Large Cap Growth ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
Optimize Strategy Index ETF
0%
Avantis US Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
View more
Federated Hermes MDT Small Cap Core ETF
Proportion0.07%
iShares Micro-Cap ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Fidelity Fundamental Large Cap Growth ETF
Proportion0%
T Rowe Price Small-Mid Cap ETF
Proportion0%
Optimize Strategy Index ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Zentalis Pharmaceuticals Inc?
The top five shareholders of Zentalis Pharmaceuticals Inc are:
Walters (William T) holds 7.05M shares, accounting for 9.77% of the total shares.
Matrix Capital Management Company, LP holds 13.96M shares, accounting for 19.35% of the total shares.
The Vanguard Group, Inc. holds 2.88M shares, accounting for 4.00% of the total shares.
Acadian Asset Management LLC holds 2.80M shares, accounting for 3.88% of the total shares.
Two Sigma Investments, LP holds 2.37M shares, accounting for 3.28% of the total shares.
Walters (William T) holds 7.05M shares, accounting for 9.77% of the total shares.
Matrix Capital Management Company, LP holds 13.96M shares, accounting for 19.35% of the total shares.
The Vanguard Group, Inc. holds 2.88M shares, accounting for 4.00% of the total shares.
Acadian Asset Management LLC holds 2.80M shares, accounting for 3.88% of the total shares.
Two Sigma Investments, LP holds 2.37M shares, accounting for 3.28% of the total shares.
What are the top three shareholder types of Zentalis Pharmaceuticals Inc?
The top three shareholder types of Zentalis Pharmaceuticals Inc are:
Walters (William T)
Matrix Capital Management Company, LP
The Vanguard Group, Inc.
Walters (William T)
Matrix Capital Management Company, LP
The Vanguard Group, Inc.
How many institutions hold shares of Zentalis Pharmaceuticals Inc (ZNTL)?
As of 2025Q3, 354 institutions hold shares of Zentalis Pharmaceuticals Inc, with a combined market value of approximately 51.80M, accounting for 71.81% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -22.17%.
What is the biggest source of revenue for Zentalis Pharmaceuticals Inc?
In FY2025Q2, the -- business generated the highest revenue for Zentalis Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
